extract: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics
Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>
This commit is contained in:
Teleo Agents
parent
bfb4eb453e
commit
bc107b0da5
6 changed files with 63 additions and 1 deletions
|
|
@ -83,6 +83,12 @@ Danish cohort achieved same weight loss outcomes (16.7% at 64 weeks) using HALF
|
|||
|
||||
BALANCE Model's dual payment mechanism (capitation adjustment + reinsurance) plus manufacturer-funded lifestyle support represents the first major policy attempt to address the chronic-use cost structure. The Medicare GLP-1 Bridge (July 2026) provides immediate price relief while full model architecture is built, indicating urgency around cost containment.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-18*
|
||||
|
||||
Medicare-specific modeling shows net savings of $715M over 10 years when multi-indication benefits are accounted for under risk-bearing payment structure, suggesting the 'inflationary through 2035' conclusion depends on payment model fragmentation rather than inherent drug economics
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -54,6 +54,12 @@ FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0
|
|||
|
||||
Quantified lifetime savings per subject: $14,431 from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events. Diabetes prevention is the dominant economic driver, not cardiovascular protection, suggesting targeting should prioritize metabolic risk over CV risk.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-18*
|
||||
|
||||
Comprehensive Medicare modeling quantifies multi-indication value: 38,950 CV events avoided, 6,180 deaths avoided, with T2D savings ($892M) exceeding obesity costs ($205M) plus MASH savings ($28M) over 10 years, demonstrating that cardiovascular and metabolic benefits compound to offset drug costs
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -40,6 +40,12 @@ FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major k
|
|||
|
||||
SELECT trial economic model shows $2,074 per-subject lifetime savings from avoided CKD, supporting the claim that kidney protection generates substantial cost savings. However, diabetes prevention ($14,431) generates even larger savings.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-18*
|
||||
|
||||
Per-subject lifetime treatment costs average $47,353, with CKD-related savings of $2,074/subject contributing to overall cost-effectiveness alongside T2D savings ($14,431/subject) and CV savings ($1,512/subject)
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -53,6 +53,12 @@ The BALANCE Model moves payment toward genuine risk by adjusting capitated rates
|
|||
|
||||
CMS BALANCE Model demonstrates policy recognition of the VBC misalignment by implementing capitation adjustment (paying plans MORE for obesity coverage) plus reinsurance (removing tail risk) rather than expecting prevention incentives to emerge from capitation alone. This is explicit structural redesign around the identified barriers.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-18*
|
||||
|
||||
Semaglutide economics demonstrate the payment boundary problem: the drug appears cost-saving under Medicare risk-bearing structure ($715M net savings) but would appear inflationary in fragmented FFS where pharmacy pays for drug while hospitals capture complication revenue
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,26 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "comprehensive-semaglutide-access-saves-medicare-through-multi-indication-cardiovascular-and-metabolic-benefits-when-single-payer-bears-both-costs-and-savings.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor",
|
||||
"opsec_internal_deal_terms"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 1,
|
||||
"kept": 0,
|
||||
"fixed": 1,
|
||||
"rejected": 1,
|
||||
"fixes_applied": [
|
||||
"comprehensive-semaglutide-access-saves-medicare-through-multi-indication-cardiovascular-and-metabolic-benefits-when-single-payer-bears-both-costs-and-savings.md:set_created:2026-03-18"
|
||||
],
|
||||
"rejections": [
|
||||
"comprehensive-semaglutide-access-saves-medicare-through-multi-indication-cardiovascular-and-metabolic-benefits-when-single-payer-bears-both-costs-and-savings.md:missing_attribution_extractor",
|
||||
"comprehensive-semaglutide-access-saves-medicare-through-multi-indication-cardiovascular-and-metabolic-benefits-when-single-payer-bears-both-costs-and-savings.md:opsec_internal_deal_terms"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-18"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2025-06-01
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: paper
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, semaglutide, medicare, cost-effectiveness, cardiovascular, CKD, MASH]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-18
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -39,3 +43,11 @@ Key findings:
|
|||
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
|
||||
WHY ARCHIVED: This study provides the strongest evidence that the "inflationary through 2035" framing needs scope qualification — system-level vs. payer-level economics diverge when downstream savings accrue to the same entity
|
||||
EXTRACTION HINT: Focus on the distinction between system-level cost impact (inflationary) and risk-bearing payer impact (potentially cost-saving). This is the core VBC interaction.
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Semaglutide Medicare modeling projects 38,950 cardiovascular events avoided over 10 years
|
||||
- Per 100,000 subjects treated: 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, 487 non-fatal strokes avoided, 115 CV deaths avoided
|
||||
- Average per-subject lifetime treatment costs: $47,353
|
||||
- T2D-related savings: $14,431/subject; CKD savings: $2,074/subject; CV savings: $1,512/subject
|
||||
- MASH-related savings are modest ($28M over 10 years) despite clinical efficacy, suggesting MASH treatment costs don't accumulate enough in 10-year window to produce large offsets
|
||||
|
|
|
|||
Loading…
Reference in a new issue